DE60019347D1 - Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion - Google Patents

Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion

Info

Publication number
DE60019347D1
DE60019347D1 DE60019347T DE60019347T DE60019347D1 DE 60019347 D1 DE60019347 D1 DE 60019347D1 DE 60019347 T DE60019347 T DE 60019347T DE 60019347 T DE60019347 T DE 60019347T DE 60019347 D1 DE60019347 D1 DE 60019347D1
Authority
DE
Germany
Prior art keywords
inhibitors
beta
alpha
cell adhesion
mediated cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019347T
Other languages
English (en)
Other versions
DE60019347T2 (de
Inventor
Ila Sircar
Marshall Morningstar
Paul Furth
Nicholas Smith
R Teegarden
C Griffith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of DE60019347D1 publication Critical patent/DE60019347D1/de
Application granted granted Critical
Publication of DE60019347T2 publication Critical patent/DE60019347T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60019347T 1999-10-20 2000-10-19 Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion Expired - Lifetime DE60019347T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16062999P 1999-10-20 1999-10-20
US160629P 1999-10-20
US20984700P 2000-06-07 2000-06-07
US209847P 2000-06-07
PCT/US2000/029273 WO2001030781A2 (en) 1999-10-20 2000-10-19 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION

Publications (2)

Publication Number Publication Date
DE60019347D1 true DE60019347D1 (de) 2005-05-12
DE60019347T2 DE60019347T2 (de) 2006-03-09

Family

ID=26857065

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019347T Expired - Lifetime DE60019347T2 (de) 1999-10-20 2000-10-19 Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion

Country Status (16)

Country Link
EP (1) EP1307455B1 (de)
JP (1) JP3943394B2 (de)
KR (1) KR100496940B1 (de)
CN (2) CN1185232C (de)
AT (1) ATE292634T1 (de)
AU (1) AU778757B2 (de)
BR (1) BR0014651A (de)
CA (1) CA2388639C (de)
DE (1) DE60019347T2 (de)
ES (1) ES2240201T3 (de)
HK (1) HK1053473A1 (de)
IL (2) IL148932A0 (de)
MX (1) MXPA02003977A (de)
NZ (1) NZ518369A (de)
PT (1) PT1307455E (de)
WO (1) WO2001030781A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292634T1 (de) * 1999-10-20 2005-04-15 Tanabe Seiyaku Co Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
AU2001281995A1 (en) * 2000-07-21 2002-02-05 Lion Bioscience Ag Bicyclic hydantoin derivatives and combinatorial libraries thereof
WO2002044181A1 (en) 2000-12-01 2002-06-06 Bristol-Myers Squibb Company Hydantoin compounds useful as anti-inflammatory agents
WO2002092606A1 (fr) * 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Derives d'imidazolidine fusionnes, leur procede de preparation et d'utilisation
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200303200A (en) * 2002-02-07 2003-09-01 Tanabe Seiyaku Co Inhibitors of α L β 2 integrin mediated cell adhesion
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1539744A4 (de) 2002-07-11 2007-06-06 Vicuron Pharm Inc N-hydroxyamidderivate mit antibakterieller wirkung
WO2004032861A2 (en) 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
US7632858B2 (en) * 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7186725B2 (en) * 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
MXPA05011353A (es) * 2003-04-22 2005-11-28 Anormed Inc Compuestos heterociclicos que se unen al receptor de quimiocina con eficacia mejorada.
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
TW200616634A (en) 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
US7186727B2 (en) 2004-12-14 2007-03-06 Bristol-Myers Squibb Company Pyridyl-substituted spiro-hydantoin compounds and use thereof
WO2006124748A2 (en) * 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Multicyclic compounds and methods of their use
CA2624488A1 (en) * 2005-10-06 2007-04-12 Novartis Ag Tetrahydro-pyrrolizinone compounds as lfa-i mediators
AU2007212191B2 (en) * 2006-02-10 2011-12-22 Janssen Pharmaceutica N.V. Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators
JPWO2008007664A1 (ja) 2006-07-11 2009-12-10 武田薬品工業株式会社 二環性複素環化合物およびその用途
JP5485164B2 (ja) 2007-11-29 2014-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ６，７−ジヒドロ−５Ｈ−イミダゾ［１，２−ａ］イミダゾール−３−カルボン酸アミドの誘導体
WO2010141273A1 (en) 2009-06-02 2010-12-09 Boehringer Ingelheim International Gmbh DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
WO2010141330A1 (en) 2009-06-02 2010-12-09 Boehringer Ingelheim International Gmbh DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
TWI537246B (zh) * 2011-07-22 2016-06-11 維南提亞有限公司 用於治療發炎性腸病之化合物
HUE053975T2 (hu) * 2013-12-09 2021-08-30 Unichem Lab Ltd Továbbfejlesztett eljárás (3R,4R)-(1-benzil-4-metilpiperidin-3-il)-metilamin elõállítására
CN106588926B (zh) * 2016-12-28 2018-10-09 华东师范大学 一种2,7-二氮杂[3,2,1]二环辛烷及其衍生物及其合成方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502813A (en) * 1997-08-22 2002-10-25 F N-aroylphenylalanine derivatives as inhibitors of the interaction between a4 containing integrins and VCAM-1
ATE292634T1 (de) * 1999-10-20 2005-04-15 Tanabe Seiyaku Co Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion

Also Published As

Publication number Publication date
CA2388639C (en) 2007-07-17
ATE292634T1 (de) 2005-04-15
HK1053473A1 (en) 2003-10-24
AU1437001A (en) 2001-05-08
JP3943394B2 (ja) 2007-07-11
KR100496940B1 (ko) 2005-06-23
CN1382143A (zh) 2002-11-27
DE60019347T2 (de) 2006-03-09
MXPA02003977A (es) 2003-09-25
CN1332961C (zh) 2007-08-22
ES2240201T3 (es) 2005-10-16
NZ518369A (en) 2003-09-26
IL148932A0 (en) 2002-09-12
CA2388639A1 (en) 2001-05-03
WO2001030781A2 (en) 2001-05-03
AU778757B2 (en) 2004-12-16
WO2001030781A3 (en) 2001-11-22
EP1307455A2 (de) 2003-05-07
KR20020068523A (ko) 2002-08-27
PT1307455E (pt) 2005-06-30
BR0014651A (pt) 2002-06-18
EP1307455B1 (de) 2005-04-06
CN1651431A (zh) 2005-08-10
CN1185232C (zh) 2005-01-19
IL148932A (en) 2006-12-31
JP2003512468A (ja) 2003-04-02

Similar Documents

Publication Publication Date Title
DE60019347D1 (de) Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
EA200500017A1 (ru) Новые соединения
ATE306261T1 (de) Antithrombosemittel
DE69830504D1 (de) Antithrombotische mitteln
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
AU4327600A (en) Aryl sulfonyls as factor xa inhibitors
PT1315694E (pt) Inibidores da adesao celular mediada por alfa 4
DE69931393D1 (de) Antithrombotische amide
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
ATE272633T1 (de) Aromatische amiden
AU2056197A (en) M-amidino phenyl analogs as factor xa inhibitors
IL156873A0 (en) Pharmaceutically active piperidine derivatives
DK1265606T3 (da) Celleadhæsionsinhibitorer
CY1108567T1 (el) Αντιθρομβωτικες ενωσεις
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
TR200001452T2 (tr) Bifenilamidin türevleri.
MXPA05005198A (es) Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina.
WO2004030664A3 (en) New compounds for the inhibition of undesired cell proliferation and use thereof
ATE308540T1 (de) Antithrombosemittel
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
DK1180094T3 (da) Kondenserede polycykliske aminosyrer som farmaceutiske midler
MXPA04007643A (es) Inhibidores de la adhesion celular mediada por integrina alb2.
GB0130868D0 (en) New compounds
ATE268322T1 (de) Inhibitoren der tryptase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition